• DOI:10.1182/BLOOD-2002-09-2778
• Corpus ID: 7756247

Utility of FDG-PET scanning in lymphoma by WHO classification.

@article{Elstrom2003UtilityOF,
  title={Utility of FDG-PET scanning in lymphoma by WHO classification.},
  author={Rebecca L. Elstrom and Liang Guan and G. Baker and Khozaim Nakhoda and J-A. Vergilio and Hongming Zhuang and Stephanie Pitsilos and Adam Bagg and Lisa H. Downs and Amit K. Mehrotra and Scott Kim and Abass Alavi and Stephen J. Schuster},
  journal={Blood},
  year={2003},
  volume={101 10},
  pages={
          3875-6
        }
}

• R. Elstrom, L. Guan, +10 authors S. Schuster
• Published 15 May 2003
• Medicine
• Blood

We retrospectively evaluated (18)fluoro-2-deoxyglucose positron emission tomography (FDG-PET) scans in 172 patients with lymphoma and correlated results with pathologic diagnosis using the World Health Organization (WHO) classification system. In total, FDG-PET detected disease in at least one site in 161 patients (94%) and failed to detect disease in 11 patients (6%). The most frequent lymphoma diagnoses were diffuse large B-cell lymphoma (LBCL; n = 51), Hodgkin lymphoma (HL; n = 47), follicular lymphoma (FL; n = 42), marginal zone lymphoma (MZL; n = 12), mantle cell lymphoma (MCL; n = 7), and peripheral T-cell lymphoma (PTCL; n = 5). FDG-PET detected disease in 100% of patients with LBCL and MCL and in 98% of patients with HL and FL. In contrast, FDG-PET detected disease in only 67% of MZL and 40% of PTCL. Comparison with bone marrow biopsies showed that FDG-PET was not reliable for detection of bone marrow involvement in any lymphoma subtype.